It has been validated in multiple studies, thereby demonstrating the robustness and potential of this fairly simple, quick and cost-effective pathological technique.15,17,18 Since the prognostic quality of the TSR is clear, it is interesting to evaluate whether this parameter could also serve as a predictive marker to improve risk stratification of patients with high-risk stage II and III colon cancer, in order to determine if subpopulations could benefit from the VEGF antibody bevacizumab in an adjuvant setting. This evidence concerns the gene VEGFA and malignant colon neoplasm.